As humans age, we become more vulnerable to cancer and other diseases. Bowhead whales, however, can live for up to 200 years ...

Hanmi Pharmaceutical, the core business subsidiary of Hanmi Science, unveiled a range of next-generation modality research achievements at a ...

A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 8.0 months. Post the September 4, 2025 data cutoff date, four uPRs were confirmed and one ...

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2 ...

LOS ANGELES and NIMES, France, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biotechnology company leveraging its proprietary targeted peptide delivery technology (PEP-NP™) to advance in vivo ...

The safety population consisted of 109 patients treated with at least one dose of rezatapopt 2000 mg daily as monotherapy. Median number of prior lines of systemic therapy was three (range: 1-10) The ...

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

A rare genetic process could be cancer’s Achilles’ heel, and scientists just figured out how to exploit it. Shutterstock Australian scientists have uncovered a powerful new way to slow the growth of ...